Market Size in 2023 | Market Forecast in 2032 | CAGR (in %) | Base Year |
---|---|---|---|
USD 4.30 Billion | USD 9.29 Billion | 9.05% | 2023 |
The global Cardiac Marker Testing market size accrued earnings worth approximately USD 4,300.5 Million in 2023 and is predicted to gain revenue of about USD 9,285.1 Million by 2032, is set to record a CAGR of nearly 9.05% over the period from 2024 to 2032.
When the heart is injured or stressed, it releases certain substances into the blood, which function as cardiac markers. The cardiac markers are usually enzymes, proteins, and hormones. Thus, quantification of these biomarkers can aid in diagnosing numerous heart disorders, including cardiac ischemia, acute coronary syndrome, and conditions linked to hindered blood supply to the heart. Physicians usually carry out multiple cardiac marker tests for hours to observe the blood level increase and to recognize the seriousness of a heart attack.
To know more about this report, request a sample copy.
The major factors boosting the growth of global cardiac marker testing include rising expenditure by different institutes to encourage clinical and research studies in biomarker testing, increasing incidence of cardiovascular disorders, and increasing elderly population. However, issues related to storage and collection of samples, compensation, and strict regulatory recommendation are few factors that can hamper the growth of the global market. In addition, estimation of cardiac marker levels in the labs requires considerable time; thus, it cannot be used in the determination of myocardial infarction during the acute phase further restraining its use.
The global market for cardiac marker testing can be segmented based on disease, type of testing, product, type, and region. The disease segment of the market is divided into congestive heart failure and myocardial infarction. The type of testing segment of the market is diversified into point-of-care testing and laboratory testing. The product segment of the cardiac marker testing market is classified into immunofluorescence, immunochromatography, instruments, reagents and kits, chemiluminescence, and enzyme-linked immunosorbent assay. The type segment of the market is divided into C-reactive protein, troponin I and T, brain natriuretic peptide or NT-proBNP, CK-MB, other biomarkers, and myoglobin. The other biomarkers segment of the market is classified into H-FABP, homocysteine, myeloperoxidase, galectin-3, and ischemia-modified albumin. Regionally, the cardiac marker testing market is diversified into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
Report Attributes | Report Details |
---|---|
Report Name | Cardiac Marker Testing Market |
Market Size in 2023 | USD 4,300.5 Million |
Market Forecast in 2032 | USD 9,285.1 Million |
Growth Rate | CAGR of 9.05% |
Number of Pages | 214 |
Key Companies Covered | Siemens AG, Abbott Laboratories, Danaher Corporation, bioMérieux SA, Alere, Inc., Roche Diagnostics Ltd., Ortho Clinical Diagnostics, LSI Medience Corporation, Randox laboratories Ltd, Guangzhou Wondfo Biotech Co., Ltd., Bio-Rad Laboratories,Inc., Helomics Corporation, Becton, Dickinson and Company, Avantra Biosciences, and Enzo Biochem. |
Segments Covered | By Type, By Product, By Disease, By Type of Testing, and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
Base Year | 2023 |
Historical Year | 2018 to 2022 |
Forecast Year | 2024 - 2032 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
Regional Analysis
North America is anticipated to dominate the global market of cardiac markers testing. The various factors contributing to the growth of the market in this region include rising aging population, increasing inclination toward point-of-care testing, and elevated frequency of cardiovascular disorders. Asia-Pacific region is also expected to grow in the global market in the near future owing to the huge population, growing incidence of chronic heart diseases, and various measures taken to increase alertness about the diagnosis of cardiac diseases at an early stage.
The key players in the global cardiac marker testing market include
Segments Covered
By Type Segment
By Product Segment
By Disease Segment
By Type of Testing Segment
FrequentlyAsked Questions
Increase in use of electronic components in various industries such as aerospace, automotive, and consumer electronics, among others. Furthermore huge demand for FMCG sector has driven the growth of Cardiac Marker Testing Market in Asia Pacific region.
Global Cardiac Marker Testing market size earned around $4.30 Bn in 2023 and is expected to reach $9.29 Bn by 2032, with a projected CAGR of 9.05%.
Emerging economies such as India and China in Asia Pacific are expecting huge growth in Cardiac Marker Testing Market. Recent technological innovation is considered as one of the major driving factor for the growth of the market.
Some main participants of the Siemens AG, Abbott Laboratories, Danaher Corporation, bioMérieux SA, Alere, Inc., Roche Diagnostics Ltd., Ortho Clinical Diagnostics, LSI Medience Corporation, and Randox laboratories Ltd. The other major players in the global market are Guangzhou Wondfo Biotech Co., Ltd., Bio-Rad Laboratories, Inc., Helomics Corporation, Becton, Dickinson and Company, Avantra Biosciences, and Enzo Biochem.
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed